{"disease":{"id":"mucopolysaccharidosis-mps-i","name":"Mucopolysaccharidosis, MPS-I","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"elosulfase-alfa","indication_name":"Mucopolysaccharidosis, MPS-IV-A","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhgalns","generic_name":"ELOSULFASE ALFA","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"N-acetylgalactosamine-6-sulfatase","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":55,"revenue":"500","mechanism":"VIMIZIM provides exogenous N-acetylgalactosamine-6-sulfatase to increase the catabolism of GAGs KS and C6S in lysosomes."},{"drug_id":"laronidase","indication_name":"Mucopolysaccharidosis, MPS-I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldurazyme","generic_name":"LARONIDASE","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":50,"revenue":"300","mechanism":"Aldurazyme breaks down abnormal sugar molecules in the body to treat Mucopolysaccharidosis I."},{"drug_id":"vestronidase-alfa","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepsevii","generic_name":"VESTRONIDASE ALFA","company_name":"Ultragenyx Pharm Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Lysosomal beta Glucuronidase [EPC]","quality_score":10,"revenue":null,"mechanism":"Mepsevii works by replacing the deficient enzyme beta-glucuronidase in patients with MPS-VII."},{"drug_id":"idursulfase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elaprase","generic_name":"IDURSULFASE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Elaprase works by replacing the deficient enzyme iduronate-2-sulfatase in the body."},{"drug_id":"vestronidase-alfa-vjbk","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEPSEVII","generic_name":"VESTRONIDASE ALFA-VJBK","company_name":"ULTRAGENYX PHARM INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"elaprase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elaprase","company_name":"Shire","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"mepsevii","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mepsevii","company_name":"Ultragenyx Pharmaceutical Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aldurazyme","indication_name":"Mucopolysaccharidosis, MPS-I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aldurazyme","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00144794","title":"Mucopolysaccharidosis I (MPS I) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1406,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT07361536","title":"Cardiac Structure and Function in MPS","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Children's Hospital of Orange County","has_results":false},{"nct_id":"NCT00630747","title":"Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT05284006","title":"Non-invasive Functional Assessment and Pathogenesis of Morquio A","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Nemours Children's Clinic","has_results":false},{"nct_id":"NCT05073783","title":"A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07136896","title":"Nutritional Assessment in Patient of Mucopolysaccharide \"","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT00607386","title":"Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03580083","title":"RGX-111 Gene Therapy in Patients With MPS I","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":21,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT01572636","title":"Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome","phase":"","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03632213","title":"Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT03041324","title":"Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Sangamo Therapeutics","has_results":true},{"nct_id":"NCT04571970","title":"RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT02618512","title":"A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}